SOURCE: Arcturus Bioscience

April 18, 2005 08:00 ET

Arcturus Presents at 2005 American Association for Cancer Research Annual Meeting

Highly Sensitive and Reproducible Expression Profiling From Formalin-Fixed, Paraffin-Embedded Tissues

MOUNTAIN VIEW, CA -- (MARKET WIRE) -- April 18, 2005 -- Researchers from Arcturus Bioscience, Inc. will present results from two studies demonstrating the use of Arcturus' novel Paradise Reagent System at the upcoming 96th Annual American Association for Cancer Research (AACR) Meeting in Anaheim, CA.

Tumor biopsies are commonly preserved as Formalin-Fixed Paraffin-Embedded (FFPE) tissues. Enabling high-throughput whole transcript (non-3'-biased) profiling of FFPE samples using quantitative real-time PCR (QRT-PCR) is important for the development of clinically meaningful molecular profiles of cancer. However, the FFPE tissue preservation compromises the extraction and isolation of RNA of adequate quality. Researchers at Arcturus recently developed and optimized a novel process that integrates efficient isolation of total cellular RNA from FFPE tissues, followed by reverse transcription of whole transcripts for quantitative real-time PCR analysis.

In these studies, Arcturus scientists provide a process for whole transcript profiling using QRT-PCR of low, medium and high abundance genes from as little as ten nanograms of total RNA using the Paradise Reagent System for FFPE Tissues. The process developed at Arcturus can be applied in clinical research to discover, develop, and validate RNA markers for cancer research and diagnostics.

The two studies: (1) "High-Throughput Whole Transcript Profiling of Microdissected Tumor Cells from Formalin-Fixed Paraffin-Embedded Sections Using Quantitative Real-Time PCR" (Abstract #4458) and (2) "Gene Expression Profiling of Murine Tumor Cells from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays" (Abstract #4453), will be presented on Tuesday, April 19th, from 1pm - 5pm at the Anaheim Convention Center.

For more information, visit the AACR Annual Meeting Site at

About Arcturus Bioscience, Inc.

Arcturus is the industry leader in Laser Capture Microdissection (LCM) and reagent systems for microgenomics, the molecular analysis of microscopic tissue samples, with systems installed in leading cancer centers, research institutions and clinical research laboratories worldwide. These tools enable researchers to perform rapid cell-based analysis of disease progression utilizing the smallest and purest samples currently available. The company has developed this unique technology platform for genetic analysis of biopsy samples and has applied its platform to discover cell-specific gene signatures associated with human diseases such as cancer. These novel gene signatures enable clinical laboratories to develop diagnostic applications for tumor identification and breast cancer prognosis. Arcturus is a private company headquartered in Mountain View, California.

Contact Information

  • Media Contact:
    Robert A. Schueren